Authored by Karl Simpson
A lack of European leadership talent is often cited by investors as a limiting factor for European biotechs. Well, seemingly they are making every success of things on the other side of the Atlantic Ocean, where the pulling power and magnetism of the thriving clusters of Boston and San Francisco continue to attract the brightest and the best.
One such company to snap up some European talent plying their trade abroad is Boston-based Genocea Biosciences. The company, which is developing T cell-enabled vaccines and immunotherapies, has hired a new Chief Financial Officer (CFO) in Jonathan Poole, an executive trained in the UK. The company appoints Mr. Poole from Shire, where he has been working in the capacity of CFO for Shire’s Human Genetic Therapies business, focused on rare diseases. This is the second significant departure from Shire’s finance management team after Graham Hetherington recently announced his decision to step down as CFO. James Bowling fulfils the role of CFO ad-interim.
In Jonathan Poole, Genocea Biosciences have appointed an experienced finance professional who brings many years working in finance with Shire, built on a previous career of investment banking with UBS, ING Barings and a UK private equity shop, Avanti Capital. He also has an MBA from LBS.
Genocea Biosciences has a pipeline of novel clinical stage assets, GEN-003 for HSV-2 therapy, GEN-004 to prevent infections causes by pneumococcus, and earlier stage programmes in chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapy.